Delivery Order SPE2DB22D2211-SPE2DB25FSCQS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $33,916.69 to AmerisourceBergen Drug Corp for VEMLIDY 25 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price contract, which is not set-aside, represents a pharmaceutical supply delivery supporting federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $3,000 to Amerisourcebergen Drug Corporation to supply 4561479431 VEMLIDY 25 MG tablets. Under the contract, Amerisourcebergen will deliver 30 tablets of VEMLIDY, an antiviral medication used to treat chronic hepatitis B virus infection, to a location in Conshohocken, Pennsylvania by July 13, 2023. The prime contractor, Amerisourcebergen Drug Corporation, is a subsidiary of Amerisourcebergen...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,643.00 for VEMLIDY 25 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a non-competitive delivery order utilizing the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The award is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania, and...
- The Defense Logistics Agency awarded a $3,798.09 firm fixed-price delivery order to AmerisourceBergen Drug Corp for VEMLIDY 25 mg tablets (30-count units) with a completion date of July 1, 2025. This non-set-aside contract represents a single delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support...
- Amerisourcebergen Drug Corporation, operating as Amerisourcebergen, has been awarded a $6,048 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical (DLA) to supply 4561773698 VEMLIDY 25 MG tablets. Performance will take place in Conshohocken, Pennsylvania over one day in August 2023. The Defense Logistics Agency Troop Support Medical supports the Department of Defense's supply chain needs. This delivery order is likely associated with DLA's pharmaceutical prime...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,206,161 units of the pharmaceutical product VEMLIDY 25 MG TABLET in 30-count packages. The $5,193.06 delivery order has a performance period through April 9, 2024. This award is part of a larger indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00...
- The Defense Logistics Agency Troop Support Medical awarded a $2,884.84 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 25 mg tablets of VEMLIDY (tenofovir alafenamide). The contract has a period of performance from September 18-19, 2023. Amerisourcebergen will deliver the VEMLIDY tablets from its facility located in Conshohocken, Pennsylvania to fulfill the agency's requirements. No major subcontractors or set aside designations were indicated. The Defense Logistics...
- The Defense Logistics Agency awarded a $19,615.57 firm fixed price delivery order to Amerisourcebergen Drug Corporation for VEMLIDY 25 MG tablets. The order is for 30 boxes of the medication and will be fulfilled from Amerisourcebergen's facility in Conshohocken, Pennsylvania by August 14, 2023. As a leading provider of pharmaceuticals and medical supplies, Amerisourcebergen will deliver the ordered VEMLIDY tablets to support the Defense Logistics Agency's mission of providing critical medical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide VEMLIDY 25 MG TABLET medication. The $7,789.59 contract has an ultimate completion date of April 4, 2024. Amerisourcebergen Drug Corp is a prime contractor that holds an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025, to deliver pharmaceutical products and...
- The U.S. Department of Defense (DoD) has awarded a $7,632.23 firm fixed price delivery order (SPE2DX15D2102|SPE2DX24F63NM) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,564,248,114 units of the pharmaceutical product VEMLIDY 25 MG TABLET. The delivery order has an ultimate completion date of April 12, 2024 and was issued under an existing $999,999,999.00 indefinite delivery contract (IDC) between AmerisourceBergen Drug Corp and the...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCQSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,164.34 to AmerisourceBergen Drug Corp for VEMLIDY 25 mg tablets (30-count units) on August 11, 2025, with a completion date of August 12, 2025. This firm fixed price delivery order represents a non-competitive award under the vendor's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. VEMLIDY (tenofovir alafenamide/emtricitabine) is an antiviral medication used in HIV treatment regimens. This delivery order exemplifies the company's ongoing role as a primary pharmaceutical supplier through the DLA's global pharmaceutical support vehicle, enabling delivery of both specialty and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/11/25 |